Invitrogen

CD106 (VCAM-1) Monoclonal Antibody (429), eBioscience™

Product Image Gallery

CD106 (VCAM-1) Antibody in Immunocytochemistry, Flow Cytometry (ICC/IF, Flow) — Figure 3 Loss of endothelial SENP1 inhibits EC activation. ( a ) Grafts from WT or SENP1-ecKO mice were harvested 3 days post-transplantation. The induction of endothelial adhesion molecules was demonstrated by immunofluorescence staining of ICAM-1, VCAM-1, or P-selectin and PECAM-1 with DAPI labelling of the nuclei. Bar represents 50 mum. ( b - e ) Attenuated induction of adhesion molecules in SENP1-ecKO MAECs. Flow cytometry analysis of ICAM-1, VCAM-1 and P-selectin in MAECs isolated from WT or SENP1-ecKO mice after TNF or IL-1beta treatment. Representative histograms are shown in ( b ) with the quantification of mean intensity in ( c - e ). ( f - h ) Overexpression of the catalytically inactive form of SENP1 (SENP1-Mut) inhibits the induction of adhesion molecules in HUVECs. HUVECs were infected by Ad-SENP1-Mut or vector control (Ad-LacZ) for 24 h, treated with pro-inflammatory cytokines and analysed by flow cytometry in the same way as MAECs. Representative histograms of ICAM-1 and VCAM-1 are shown in ( f ) with the quantification of mean intensity in ( g , h ). Data are presented as the mean+-s.e.m. from at least three independent experiments. * P <0.05 and ** P <0.01; two-way ANOVA followed by Bonferroni post-test. MAEC, mouse aortic endothelial cell.

CD106 (VCAM-1) Antibody in Immunohistochemistry (IHC) — Figure 6 Changes in aortic root and aortic arch mRNA expression for cytokines and adhesion molecules (tumor necrosis factor alpha, chemokine (C-C motif) ligand 2, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1) determined using RT-PCR in wild-type mice. (A) Relative expression at days 1, 3 and 5 days are presented. CCL2, Chemokine (C-C motif) ligand 2; CLP, Cecal ligation and puncture; TNF-alpha, Tumor necrosis factor alpha. Immunofluorescent images of the aortic root obtained to determine the expression of adhesion molecules intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) (left to right: secondary antibody-only control, sham, cecal ligation and puncture (CLP)). ICAM-1 is shown in green, VCAM-1 in red and nuclear material in blue (4',6-diamidino-2-phenylindole dihydrochloride (DAPI)). Inset shows possible colocalization of ICAM-1 with VCAM-1. (B) Graph presents cell adhesion to inflamed aortic endothelium at days 1, 3 and 5 days. Representative images show monocyte adhesion to the endothelium by day 5 (* P < 0.05 compared to the time-matched sham-treated groups).

CD106 (VCAM-1) Antibody in Flow Cytometry (Flow) — Published figure using CD106 (VCAM-1) monoclonal antibody (Product # 14-1061-82) in Flow Cytometry

Product Details

Applications

Tested Dilution

Publications

Immunohistochemistry (IHC)

View 4 publications 4 publications

Immunohistochemistry (Paraffin) (IHC (P))

View 1 publication 1 publication

Immunohistochemistry (Frozen) (IHC (F))

Assay-Dependent

Immunocytochemistry (ICC/IF)

View 1 publication 1 publication

Flow Cytometry (Flow)

0.25 µg/test

View 8 publications 8 publications

Immunoprecipitation (IP)

Assay-Dependent

Neutralization (Neu)

Assay-Dependent

View 1 publication 1 publication

Functional Assay (FN)

Assay-Dependent

Product Specifications

Species Reactivity

Mouse

Published species

Human, Mouse

Host/Isotype

Rat / IgG2a, kappa

Class

Monoclonal

Type

Antibody

Clone

429

Conjugate

Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

RRID

AB_467419

Product Specific Information

Description: The 429 monoclonal antibody reacts with mouse CD106 (Vascular Cell Adhesion Molecule-1, VCAM-1), a 110 kDa transmembrane glycoprotein expressed by myeloid lineage and bone marrow stromal cells. Endothelial cells constitutively express low levels of CD106 and upregulate it upon cytokine stimulation. CD106 binds to integrin alpha4beta1 (VLA-4, CD49d/CD29) and Integrin a4b7 (LPAM-1) and these interactions in the bone marrow and thymus are important for early lymphocyte and myeloid development. Cytokine-mediated upregulation of CD106 on endothelial cells suggests a role for this antigen in the inflammatory response.

Applications Reported: This 429 antibody has been reported for use in flow cytometric analysis, immunoprecipitation, and immunohistochemical staining of frozen tissue sections (IHC-F). It has also been reported in blocking of CD106 in functional studies. (Please use Functional Grade purified 429, cat. 16-1061, in functional assays.).

Applications Tested: The 429 antibody has been tested by flow cytometric analysis of mouse bone marrow cells. This can be used at less than or equal to 0.25 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

VCAM-1 is a cell surface sialoglycoprotein expressed by cytokine activated endothelium. The protein has a number of functions including the regulation of leukocyte migration, leukocyte-endothelial cell adhesion and signal transduction and may play a role in a number of inflammatory diseases.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.